PHI-55 A PAHSE 1 STUDY OF HALINCHRONDRIN B ANALOG (E7389) IN COMBINATION W

PHI-55 A HALINCHRONDRIN B 类似物 (E7389) 与 W 组合的第 1 阶段研究

• 批准号: 7982127
• 负责人: HEINZ JOSEF LENZ
• 金额: $ 2.67万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982127
• 关键词: Cisplatin; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Drug Kinetics; E7389; Funding; Gene Expression; Grant; Institution; Paraffin Embedding; Phase I Clinical Trials; Research; Research Personnel; Resources; Safety; Source; Toxic effect; United States National Institutes of Health; analog; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase 1 study using the combination E7289 (halinchrondrin) with cisplatin. The study will estimate the MTD of this combination. Safety and toxicity of the combination will be assessed. Pharmacokinetics will be performed on cycle 1, day 15. Paraffin embedded archival tumor will be submitted to study gene expression.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是一项使用Cisplatin组合E7289（Halinchrondrin）组合的1阶段研究。该研究将估计该组合的MTD。将评估组合的安全性和毒性。药代动力学将在第1循环第15天进行。石蜡嵌入的档案肿瘤将提交研究基因表达。